Role of epicardial adipose tissue in the pathogenesis of chronic inflammation in heart failure with preserved ejection fraction

According to the recent World Health Organization statistics, cardiovascular disease (CVD) is one of the leading causes of high mortality worldwide. While obesity is a major and persistent risk factor for CVD, the cause of this condition, the pathological molecular connection between peripheral fat depots and the heart, remains poorly understood. The aim of this review is to introduce the reader to the metabolic activity of epicardial adipose tissue (EAT), the consequences of excessive epicardial fat accumulation and the development of heart failure (HF).

EAT is visceral adipose tissue that is in direct contact with the myocardium and coronary vessels and can influence cardiac function through both mechanical effects and more subtle paracrine molecular mechanisms. HF with preserved ejection fraction (HFpEF) is closely associated with obesity and patterns in fat distribution. Excessive amounts of EAT are associated with abnormal hemodynamics in HFpEF, with the potential for direct mechanical effects on the heart causing a constriction-like effect and local myocardial remodeling effects resulting from the secretion of inflammatory mediators. However, patients with excess EAT tend to have more subcutaneous adipose tissue, making it difficult to determine a cause-and-effect relationship between epicardial fat and HFpEF. This review provides evidence that excess EAT is an important part of HFpEF pathogenesis.

1. The team of authors. Obesity in the Russian population during the COVID-19 pandemic and associated factors. Data from the ESSE-RF3 study. Cardiovascular Therapy and Prevention. 2023;22(8S):3793. (In Russ.) doi:10.15829/1728-8800-2023-3793.

2. Obokata M, Reddy YNV, Pislaru SV, et al. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136:6-19. doi:10.1161/CIRCULATIONAHA.116.026807.

3. Reddy YNV, Lewis GD, Shah SJ, et al. Characterization of the obese phenotype of heart failure with preserved ejection fraction: a RELAX trial ancillary study. Mayo Clin Proc. 2019;94:1199-209. doi:10.1016/j.mayocp.2018.11.037.

4. Ageev FT, Ovchinnikov AG. Heart Failure With Low and Preserved Left Ventricular Ejection Fraction — are These Two Different Independent Diseases or One Disease, but at Different Stages of its Progression? How Does This Affect the Choice of Therapy and Its Effectiveness? Kardiologiia. 2023;63(10):4-8. (In Russ.) doi:10.18087/cardio.2023.10.n2553.

5. Tromp J, MacDonald MR, Tay WT, et al. Heart failure with preserved ejection fraction in the young. Circulation. 2018;138: 2763-73. doi:10.1161/CIRCULATIONAHA.118.034720.

6. Gorter TM, van Woerden G, Rienstra M, et al. Epicardial adipose tissue and invasive hemodynamics in heart failure with preserved ejection fraction. JACC Heart Fail. 2020;8:667-76. doi:10.1016/j.jchf.2020.06.003.

7. van Woerden G, Gorter TM, Westenbrink BD, et al. Epicardial fat in heart failure patients with mid-range and preserved ejection fraction. Eur J Heart Fail. 2018;20:1559-66. doi:10.1002/ejhf.1283.

8. van Woerden G, van Veldhuisen DJ, Manintveld OC, et al. Epicardial adipose tissue and outcome in heart failure with mid-range and preserved ejection fraction. Circ Heart Fail. 2022;15:e009238. doi:10.1161/CIRCHEARTFAILURE.121.009238.

9. Akoumianakis I, Antoniades C. The interplay between adipose tissue and the cardiovascular system: Is fat always bad? Cardiovasc Res. 2017;113(9):999-1008. doi:10.1093/cvr/cvx111.

10. Després JP. Body fat distribution and risk of cardiovascular disease. Circulation 2012;126(10):1301-13. doi:10.1161/circulationaha.111.067264.

11. Romantsova TI. Adipose tissue: colors, depots and functions. Obesity and metabolism. 2021;18(3):282-301. (In Russ.) doi:10.14341/omet12748.

12. van Wagoner DR. Paracrine signals modulate atrial epicardial progenitor cells and development of subepicardial adiposity and fibrosis implications for atrial fibrillation. Circ Res. 2020;126: 1343-5. doi:10.1161/CIRCRESAHA.120.317007.

13. Pugliese NR, Paneni F, Mazzola M, et al. Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. Eur J Heart Fail. 2021;23: 1858-71. doi:10.1002/ejhf.2337.

14. Spadaro J, Bing OH, Gaasch WH, Weintraub RM. Pericardial modulation of right and left ventricular diastolic interaction. Circ Res. 1981;48:233-8. doi:10.1161/01.res.48.2.233.

15. Drapkina OM, Angarsky RK, Rogozhkina EA et al. Ultrasound-assisted assessment of visceral and subcutaneous adipose tissue thickness. Methodological guidelines. Cardiovascular Therapy and Prevention. 2023;22(3):3552. (In Russ.) doi:10.15829/1728-8800-2023-3552.

16. Dzhioeva ON, Maksimova OA, Rogozhkina EA, Drapkina OM. Aspects of transthoracic echocardiography protocol in obese patients. Russian Journal of Cardiology. 2022;27(12):5243. (In Russ.) doi:10.15829/1560-4071-2022-5243.

17. Reddy YNV, Obokata M, Wiley B, et al. The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction. Eur Heart J. 2019;40:3721-30. doi:10.1093/eurheartj/ehz713.

18. Koepp KE, Obokata M, Reddy YNV, Olson TP, Borlaug BA. Hemodynamic and Functional Impact of Epicardial Adipose Tissue in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail. 2020;8(8):657-66. doi:10.1016/j.jchf.2020.04.016.

19. Pugliese NR, Mazzola M, Madonna R, et al. Exercise-induced pulmonary hypertension in HFpEF and HFrEF: different pathophysiologic mechanism behind similar functional impairment. Vascul Pharmacol. 2022;144:106978. doi:10.1016/j.vph.2022.106978.

20. Kenchaiah S, Ding J, Carr JJ, et al. Pericardial fat and the risk of heart failure. J Am Coll Cardiol. 2021;77:2638-52. doi:10.1016/j.jacc.2021.04.003.

21. Rogozhkina EA, Dzhioeva ON, Angarsky RK, et al. Comparative assessment of echocardiographic parameters in persons without diagnosed chronic non-communicable diseases depending on body mass index. The Siberian Journal of Clinical and Experimental Medicine. 2023;38(3):153-62. (In Russ.) doi:10.29001/2073-8552-2023-39-3-153-162.

22. Antonopoulos AS, Margaritis M, Verheule S, et al. Mutual regulation of epicardial adipose tissue and myocardial redox state by PPAR-γ/adiponectin signalling. Circ Res. 2016;118(5):842-55. doi:10.1161/CIRCRESAHA.115.307856.

23. Baltruniene V, Bironaitė D, Kazukauskiene I, et al. The role of serum adiponectin for outcome prediction in patients with dilated cardiomyopathy and advanced heart failure. Biomed Res Int. 2017;2017:3818292. doi:10.1155/2017/3818292.

24. Chen Y, Liu F, Han F, et al. Omentin-1 is associated with atrial fibrillation in patients with cardiac valve disease. BMC Cardiovasc Disord. 2020;20(1):214. doi:10.1186/s12872-020-01478-1.

25. Zhao A, Xiao H, Zhu Y, et al. Omentin-1: a newly discovered warrior against metabolic related diseases. Expert Opin Ther Targets. 2022;26(3):275-89. doi:10.1080/14728222.2022.2037556.

26. Zhou H, Zhang Z, Qian G, et al. Omentin-1 attenuates adipose tissue inflammation via restoration of TXNIP/NLRP3 signaling in high-fat diet-induced obese mice. Fundam Clin Pharmacol. 2020;34(6):721-35. doi:10.1111/fcp.12575.

27. Xu F, Li FX, Lin X, et al. Adipose tissue-derived omentin-1 attenuates arterial calcification via AMPK/Akt signaling pathway. Aging (Albany NY). 2019;11(20):8760-76. doi:10.18632/aging.102251.

28. Ke X, Hao Y, Li B, et al. Vaspin prevents tumor necrosis factor-α-induced apoptosis in cardiomyocytes by promoting autophagy. J. Cardiovasc Pharmacol. 2018;77(5):257-67. doi:10.1097/FJC.0000000000000562.

29. Li X, Ke X, Li Z, et al. (2019). Vaspin prevents myocardial injury in rats model of diabetic cardiomyopathy by enhancing autophagy and inhibiting inflammation. Biochem. Biophys Res Commun. 2019;514(1):1-8. doi:10.1016/j.bbrc.2019.04.110.

30. Gruzdeva OV, Dyleva YA, Belik EV, et al. Relationship between epicardial and coronary adipose tissue and the expression of adiponectin, leptin, and interleukin 6 in patients with coronary artery disease. J Pers Med. 2022;12(2):129. doi:10.3390/jpm12020129.

31. Karayannis G, Giamouzis G, Tziolas N, et al. Association between epicardial fat thickness and weight homeostasis hormones in patients with noncachectic heart failure. Angiology. 2013;64(3):173-80. doi:10.1177/0003319712447978.

32. Pinieiro R, Iglesias MJ, Eiras S, et al. Leptin does not induce hypertrophy, cell cycle alterations, or production of MCP-1 in cultured rat and mouse cardiomyocytes. Endocr Res. 2005;31(4):375-86. doi:10.1080/07435800500456937.

33. Rajendran K, Devarajan N, Ganesan M, et al. Obesity, Inflammation and Acute Myocardial Infarction — Expression of leptin, IL-6 and high sensitivity-CRP in Chennai based population. Thromb J. 2012;10(1):13. doi:10.1186/1477-9560-10-13.

34. Butler J, Kalogeropoulos A, Georgiopoulou V, et al. Serum resistin concentrations and risk of new onset heart failure in older persons: The health, aging, and body composition (health ABC) study. Arterioscler Thromb Vasc Biol. 2009;29(7):1144-9. doi:10.1161/ATVBAHA.109.186783.

35. Park HK, Ahima RS. Resistin in rodents and humans. Diabetes Metab. J. 2013;37 (6):404-14. doi:10.4093/dmj.2013.37.6.404.

36. Zhao B, Bouchareb R, Lebeche D. Resistin deletion protects against heart failure injury by targeting DNA damage response. Cardiovasc Res. 2022;118(8):1947-63. doi:10.1093/cvr/cvab234.

37. Mouton AJ, Li X, Hall ME, et al. Obesity, Hypertension, and Cardiac Dysfunction: Novel Roles of Immunometabolism in Macrophage Activation and Inflammation. Circ Res. 2020;126(6): 789-806. doi:10.1161/CIRCRESAHA.119.312321.

38. Ridker PM, Rane M. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. Circ Res. 2021;128(11):1728-46. doi:10.1161/CIRCRESAHA.121.319077.

39. Segiet OA, Piecuch A, Mielańczyk Ł, et al. Role of interleukins in heart failure with reduced ejection fraction. Anatol J Cardiol. 2019;22(6):287-99. doi:10.14744/AnatolJCardiol.2019.32748.

40. Whitham M, Pal M, Petzold T, et al. Adipocyte-specific deletion of IL-6 does not attenuate obesity-induced weight gain or glucose intolerance in mice. Am J Physiol-Endocrinol Metab. 2019;317(4):597-604. doi:10.1152/ajpendo.00206.2019.

41. Markousis-Mavrogenis G, Tromp J, Ouwerkerk W, et al. The clinical significance of interleukin-6 in heart failure: Results from the BIOSTAT-CHF study. Eur J Heart Fail. 2019;21(8):965-73. doi:10.1002/ejhf.1482.

42. Cohen JB, Schrauben SJ, Zhao L, et al. Clinical phenogroups in heart failure with preserved ejection fraction: Detailed phenotypes, prognosis, and response to spironolactone. JACC Heart Fail. 2020;8(3):172-84. doi:10.1016/j.jchf.2019.09.009.

43. Liddle DM, Monk JM, Hutchinson AL, et al. CD8+ T cell/adipocyte inflammatory cross talk and ensuing M1 macrophage polarization are reduced by fish-oil-derived n-3 polyunsaturated fatty acids, in part by a TNF-α-dependent mechanism. J Nutr Biochem. 2020;76:108243. doi:10.1016/j.jnutbio.2019.108243.

44. Artemyeva OV, Gankovskaya LV. Inflammagingas the basis of age-associated diseases. Medical Immunology (Russia)/Meditsinskaya Immunologiya. 2020;22(3):419-32. (In Russ.) doi:10.15789/1563-0625-IAT-1938.

45. Vandanmagsar B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011;17(2):179-88. doi:10.1038/nm.2279.

46. Jahng JWS, Song E, Sweeney G. Crosstalk between the heart and peripheral organs in heart failure. Exp Mol Med. 2016;48(3):e217. doi:10.1038/emm.2016.20.

47. Blumensatt M, Greulich S, Herzfeld de Wiza D, et al. Activin A impairs insulin action in cardiomyocytes via up-regulation of miR-143. Cardiovasc Res. 2013;100(2):201-10. doi:10.1093/cvr/cvt173.

48. Zeller J, Krüger C, Lamounier-Zepter V, et al. The adipo-fibrokine activin A is associated with metabolic abnormalities and left ventricular diastolic dysfunction in obese patients. Esc Heart Fail. 2019;6(2):362-70. doi:10.1002/ehf2.12409.

49. Mahajan R, Nelson A, Pathak RK, et al. Electroanatomical remodeling of the atria in obesity: impact of adjacent epicardial fat. JACC Clin Electrophysiol. 2018;4:1529-40. doi:10.1016/j.jacep.2018.08.014.

50. Bartel DP. Metazoan MicroRNAs. Cell. 2018;173(1):20-51. doi:10.1016/j.cell.2018.03.006.

51. Kiran S, Kumar V, Kumar S, et al. Adipocyte, Immune Cells, and miRNA Crosstalk: A Novel Regulator of Metabolic Dysfunction and Obesity. Cells. 2021;10(5):1004. doi:10.3390/cells10051004.

52. Sanchez-Ceinos J, Rangel-Zuñiga OA, Clemente-Postigo M, et al. miR-223-3p as a potential biomarker and player for adipose tissue dysfunction preceding type 2 diabetes onset. Mol Ther Nucleic Acids. 2021;23:1035-52. doi:10.1016/j.omtn.2021.01.014.

53. Gan L, Xie D, Liu J, et al. Small Extracellular Microvesicles Mediated Pathological Communications Between Dysfunctional Adipocytes and Cardiomyocytes as a Novel Mechanism Exacerbating Ischemia/Reperfusion Injury in Diabetic Mice. Circulation. 2020;141(12):968-83. doi:10.1161/CIRCULATIONAHA.119.042640.